Navigation Links
Inverness Medical Innovations Announces Second Quarter 2008 Results
Date:7/29/2008

t income per common share for the six months ended June

30, 2007, on an adjusted cash basis, are dilutive shares consisting of

1,796,000 common stock equivalent shares from the potential exercise of

stock options and warrants. Potential dilutive shares consisting of

761,000 common stock equivalent shares from the potential conversion of

convertible debt securities for the six months ended June 30, 2007 were

not used in the calculation of diluted net income per common share, on an

adjusted cash basis, because inclusion thereof would be antidilutive.

Inverness Medical Innovations, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in $000s)

June 30, December 31,

2008 2007

(unaudited)

ASSETS

CURRENT ASSETS:

Cash and cash equivalents $167,234 $414,732

Restricted cash 3,401 141,869

Marketable securities 1,864 2,551

Accounts receivable, net 256,118 163,380

Inventories, net 180,248 148,231

Prepaid expenses and other current assets 121,566 82,211

Total current assets 730,431 952,974

PROPERTY, PLANT AND EQUIPMENT, NET 285,916 267,880

GOODWILL AND OTHER INTANGIBLE ASSETS, NET 4,793,183 3,494,174

DEFERRED FINANCING COSTS AND OTHER

ASSETS, NET 132,537 165,731

Total assets $5,942,067 $4,880,759

LIABILITIES AND STOCKHOLDERS' EQUITY

CU
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... April 30, 2015 WuXi PharmaTech (Cayman) Inc. ... leading global contract R&D services provider, today announced that ... proposal letter, dated April 29, 2015, from a consortium ... (the "Chairman"), founder, chairman and chief executive officer of ... that proposes a transaction (the "Transaction") involving the acquisition ...
(Date:4/30/2015)... 2015 Available in select spas ... , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield Cream ... while battling the weakening threat of inflammaging, aging ... formulated with star ingredient GLYCOSEA, a complex of ... complex of soothing minerals and trace elements. GLYCOSEA ...
(Date:4/30/2015)... California (PRWEB) April 30, 2015 ... 2015 PharmaSUG Annual Conference held in Orlando, ... of Staffing Solutions along with Leslie Kolman, Manager of ... the latest Clinovo news at Booth #17. , ... Annual Conference again this year”, Says Trisha Heredia, Senior ...
(Date:4/29/2015)... (PRWEB) April 30, 2015 According ... Equipment Market by Product (Portable & Non-Portable), Component ... Defense, Automotive, Chemical, Metal & Mining, & Others), ... total market is expected to reach $1,453.76 Million ... Browse 71 market data tables and 92 figures ...
Breaking Biology Technology:WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4
... Ill., May 28 Abbott will present,at the ... June 10, 2008. Thomas C. Freyman, executive vice ... presentation on the,company at 3:20 p.m. Central time., ... will be accessible through,Abbott,s Investor Relations Web site ...
... May 28 National Stem Cell,Holding, Inc. (OTC: NHGI ... to,change its name to Proteonomix, Inc. The change will ... Cohen, President/CEO, stated: "Our new name reflects the fact,that ... stage and,commencing the commercialization of our technologies. These technologies,relate ...
... -, - Three Poster Presentations on the Hydrogel ... Inc. (Amex: ULU ),today announced that at the upcoming ... 28th to June 1, 2008, Dr. John St. John, ULURU,s,Vice ... with the presentation of three posters., The title of ...
Cached Biology Technology:National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc. 2National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc. 3ULURU Inc. to Present at the 8th World Biomaterials Congress 2ULURU Inc. to Present at the 8th World Biomaterials Congress 3
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/17/2015)... BURNABY, Canada , April 17, 2015 /PRNewswire/ ... projects, growing security concerns, and technological advancement to ... Arabia until 2020   ... " Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric ... is projected to register growth at CAGR ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... Federal government changes to Canada,s fisheries legislation "have ... of the country,s fish species, scientists at the ... a new study. The changes were "politically ... government policy and are inconsistent with ecosystem-based ...
... Professor Catherine Pickering, said the Griffith study looked at ... be dispersed through horse manure. The findings have been ... . "We reviewed 15 studies on seed germination ... America, three from Australia and one study each from ...
... , Nov. 7, 2013  KaloBios Pharmaceuticals, Inc. (Nasdaq: ... its ongoing Phase 1 trial of KB004, an anti-EphA3 ... session at the 55 th American Society of ... trial of KB004 is a multi-center, dose-escalation study evaluating ...
Cached Biology News:Changes to fisheries legislation have removed habitat protection for most fish species in Canada 2Saddling up against the threat to our National Parks 2KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 2KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 3KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 4KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 5
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
... The Transcend Non-Radioactive Translation Detection ... synthesized in vitro. Using these systems, ... nascent proteins during translation, eliminating the ... other radioactive amino acids. This biotinylated ...
... The GenePix Professional 4200A can be upgraded ... Autoloader automatically loads, scans, analyzes, and saves ... notifies you by email when the batch ... uniformity, even for warped slides. GenePix Pro ...
...
Biology Products: